Production of medicines in Bashkiria more than quadrupled in July

The index of industrial production in the pharmaceutical industry in July 2021 in Bashkiria amounted to 440% compared to the same period last year. From January to July 2021, pharmaceutical production showed an increase of 71.1%. This happened due to the start of production of a vaccine against coronavirus, as well as an increase in the production of drugs for the treatment of the digestive tract, respiratory and nervous systems, the press service of the Ministry of Industry, Energy and Innovation of the Republic of Belarus reported.

“The growth of the industrial production index was expected. Our leading pharmaceutical enterprises in the region - the branch of JSC NPO Microgen in Ufa Immunopreparat and JSC Pharmstandard-UfaVITA are actively developing, modernizing, and of course, in such a difficult epidemiological situation, they supply the vaccine against both coronavirus infection and from other infectious diseases,” said the head of the Ministry of Industry of Bashkiria Alexander Sheldyaev.

The industrial production index at the Ufa branch of NPO Microgen, the Immunopreparat plant, amounted to 121% for seven months of 2021. The production of the main types of products in physical terms increased by 34.2%. At Pharmstandard-UfaVITA, the industrial production index was 180%. This plant began producing vaccines against COVID-19 - Sputnik V (Gam-COVID-Vak) and Sputnik Light.

Both companies are implementing large investment projects. Thus, at Pharmstandard-UfaVITA, the volume of investments in fixed assets this year will amount to 710 million rubles, which is 19.5% more than in 2020. Of these, 250 million rubles were invested in the reconstruction of the preliminary wastewater treatment system. Another 60 million rubles were invested in the creation of workshop No. 6, where medicines in the form of tablets will be produced. The capacity of the new production is 3 billion tablets per year. The total investment in the project is 1.347 billion rubles.

In addition, the company is building a new production site for the production of a blood coagulation factor 8 drug. The planned investment for 2021 is 1.14 billion rubles. Commissioning is scheduled for the third quarter of 2022.